Palonosetron HydrochlorideThird Party Manufacturing in India

Palonosetron Hydrochloride works by selectively blocking serotonin 5-HT₃ receptors located both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone.

By inhibiting these receptors, it effectively prevents serotonin-mediated signaling pathways that induce the nausea and vomiting reflex during and after emetogenic treatments. This action provides powerful antiemetic protection.

Unlike older generations of antiemetics, Palonosetron exhibits a stronger binding affinity and a longer half-life, making it highly effective for both acute and delayed chemotherapy-induced nausea and vomiting (CINV). It is well-tolerated and widely used to improve patient outcomes during intensive therapeutic regimens.

Therapeutic Uses

Palonosetron Hydrochloride is prescribed for the treatment of:

• Chemotherapy-Induced Nausea and Vomiting (CINV): Prevents both acute and delayed emesis associated with moderate to highly emetogenic cancer chemotherapy.
• Postoperative Nausea and Vomiting (PONV): Prevents nausea and vomiting up to 24 hours following surgical procedures.

Why Manufacturers Choose Palonosetron Hydrochloride

Palonosetron is highly valued due to its extended half-life and superior receptor binding compared to first-generation 5-HT₃ antagonists. It has become a standard of care in oncology support, maintaining consistent high demand.

This makes Palonosetron Hydrochloride one of the most sought-after molecules for third party manufacturing in India, with steady requirements from critical care and oncology-focused pharmaceutical companies.